Smith Group Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $689K | Buy |
3,169
+942
| +42% | +$209K | 0.04% | 112 |
|
|
2025
Q4 | $509K | Buy |
2,227
+177
| +9% | +$40.3K | 0.03% | 133 |
|
|
2025
Q3 | $475K | Buy |
2,050
+200
| +11% | +$40.7K | 0.03% | 136 |
|
|
2025
Q2 | $343K | Sell |
1,850
-40
| -2% | -$7.43K | 0.02% | 148 |
|
|
2025
Q1 | $396K | Sell |
1,890
-1,610
| -46% | -$313K | 0.03% | 157 |
|
|
2024
Q4 | $622K | Sell |
3,500
-670
| -16% | -$123K | 0.05% | 123 |
|
|
2024
Q3 | $823K | Buy |
4,170
+60
| +1% | +$11.2K | 0.07% | 70 |
|
|
2024
Q2 | $705K | Sell |
4,110
-130
| -3% | -$21.5K | 0.06% | 67 |
|
|
2024
Q1 | $772K | Buy |
4,240
+2,150
| +103% | +$371K | 0.04% | 119 |
|
|
2023
Q4 | $324K | Buy |
+2,090
| New | +$305K | 0.02% | 160 |
|
|
2022
Q1 | $328K | Buy |
2,021
+1,181
| +141% | +$172K | 0.02% | 136 |
|
|
2021
Q4 | $1.4M | Buy |
840
+729
| +657% | +$86.1K | 0.06% | 92 |
|
|
2021
Q3 | $12K | Sell |
111
-187,286
| -100% | -$21.4M | ﹤0.01% | 287 |
|
|
2021
Q2 | $21.1M | Sell |
187,397
-3,044
| -2% | -$343K | 1.04% | 36 |
|
|
2021
Q1 | $20.6M | Sell |
190,441
-4,569
| -2% | -$489K | 1.09% | 36 |
|
|
2020
Q4 | $20.9M | Sell |
195,010
-141,889
| -42% | -$13.6M | 1.21% | 31 |
|
|
2020
Q3 | $29.5M | Buy |
336,899
+142,157
| +73% | +$13.4M | 1.54% | 18 |
|
|
2020
Q2 | $19.1M | Buy |
194,742
+55,270
| +40% | +$4.87M | 1.05% | 32 |
|
|
2020
Q1 | $10.6M | Sell |
139,472
-97,910
| -41% | -$8.34M | 0.58% | 49 |
|
|
2019
Q4 | $21M | Buy |
237,382
+18,450
| +8% | +$1.53M | 0.88% | 45 |
|
|
2019
Q3 | $16.6M | Buy |
218,932
+105,639
| +93% | +$7.24M | 0.58% | 63 |
|
|
2019
Q2 | $8.24M | Buy |
113,293
+113,250
| +263,372% | +$8.9M | 0.28% | 90 |
|
|
2019
Q1 | $3K | Hold |
43
| – | – | ﹤0.01% | 437 |
|
|
2018
Q4 | $4K | Sell |
43
-104,190
| -100% | -$9.16M | ﹤0.01% | 418 |
|
|
2018
Q3 | $9.86M | Sell |
104,233
-30,049
| -22% | -$2.85M | 0.28% | 79 |
|
|
2018
Q2 | $12.4M | Buy |
134,282
+134,230
| +258,135% | +$13.1M | 0.36% | 70 |
|
|
2018
Q1 | $5K | Sell |
52
-93,870
| -100% | -$10.3M | ﹤0.01% | 424 |
|
|
2017
Q4 | $9.08M | Buy |
93,922
+93,870
| +180,519% | +$8.85M | 0.29% | 81 |
|
|
2017
Q3 | $5K | Hold |
52
| – | – | ﹤0.01% | 432 |
|
|
2017
Q2 | $4K | Sell |
52
-90
| -63% | -$6.05K | ﹤0.01% | 432 |
|
|
2017
Q1 | $9K | Buy |
+142
| New | +$8.93K | ﹤0.01% | 422 |
|
|
2016
Q2 | – | Sell |
-1,026,178
| Closed | -$58.6M | – | 470 |
|
|
2016
Q1 | $58.6M | Sell |
1,026,178
-272
| -0% | -$15.2K | 1.75% | 13 |
|
|
2015
Q4 | $60.8M | Buy |
1,026,450
+294,980
| +40% | +$17M | 1.8% | 10 |
|
|
2015
Q3 | $39.8M | Sell |
731,470
-61,500
| -8% | -$4M | 1.51% | 13 |
|
|
2015
Q2 | $53.3M | Buy |
792,970
+555,730
| +234% | +$36.3M | 1.8% | 10 |
|
|
2015
Q1 | $13.9M | Hold |
237,240
| – | – | 0.46% | 77 |
|
|
2014
Q4 | $15.5M | Buy |
+237,240
| New | +$15M | 0.54% | 69 |
|
Other funds holding ABBV
VCM
VPM
Smith Group Asset Management's ABBV Position: Q1 2026 in Review
Smith Group Asset Management increased its AbbVie (ABBV) stake by 42% in Q1 2026, buying an estimated $209K and bringing the position to 3,169 shares worth $689K. The position accounts for 0.04% of the portfolio, ranked #112.
Smith Group Asset Management first reported a position in ABBV in Q4 2014 and has held it in 37 quarters since. The position peaked at $60.8M in Q4 2015. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Smith Group Asset Management held 3,169 shares of AbbVie worth $689K as of Q1 2026.
- Smith Group Asset Management bought 942 AbbVie shares in Q1 2026, an estimated $209K.
- AbbVie made up 0.04% of Smith Group Asset Management's portfolio in Q1 2026, its #112 holding.
- Smith Group Asset Management first reported a position in AbbVie in Q4 2014 and has held it in 37 quarters since.
- Smith Group Asset Management's AbbVie position peaked at $60.8M in Q4 2015.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Smith Group Asset Management's 13F filing for Q1 2026, filed 18 May 2026.